Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Fig. 1

Main targets of approved anti-angiogenic receptor tyrosine kinase inhibitors (TKIs). All approved anti-angiogenic receptor TKIs can target multiple receptor sites simultaneously. The main targets included vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), c-Kit, and c-Met. Anti-angiogenic TKIs block the kinase activity of receptor and transduction of downstream signal involved in the proliferation, migration, and survival

Back to article page